Bronte Capital Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Bronte Capital Management's NKTR Position: Q3 2026 in Review
Bronte Capital Management increased its Nektar Therapeutics (NKTR) stake by 1.8% in Q3 2026, buying an estimated $254K and bringing the position to 202,057 shares worth $12.2M. The position accounts for 1.23% of the portfolio, ranked #20.
Bronte Capital Management first reported a position in NKTR in Q1 2026 and has held it in 3 quarters since. The position peaked at $14.3M in Q1 2026. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- Bronte Capital Management held 202,057 shares of Nektar Therapeutics worth $12.2M as of Q3 2026.
- Bronte Capital Management bought 3,623 Nektar Therapeutics shares in Q3 2026, an estimated $254K.
- Nektar Therapeutics made up 1.23% of Bronte Capital Management's portfolio in Q3 2026, its #20 holding.
- Bronte Capital Management first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Bronte Capital Management's Nektar Therapeutics position peaked at $14.3M in Q1 2026.
- 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on Bronte Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.